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Requirement for Neutralizing Antibodies to Control Bone
Marrow Transplantation-Associated Persistent Viral Infection
and to Reduce Immunopathology1
Karl S. Lang,2,3 Mike Recher,2 Alexander A. Navarini,2 Stefan Freigang, Nicola L. Harris,
Maries van den Broek, Bernhard Odermatt, Hans Hengartner, and Rolf M. Zinkernagel
Bone marrow transplantation (BMT) is commonly used in the treatment of leukemia, however its therapeutic application is partly
limited by the high incidence of associated opportunistic infections. We modeled this clinical situation by infecting mice that
underwent BMT with lymphocytic choriomeningitis virus (LCMV) and investigated the potential of immunotherapeutic strategies
to counter such infections. All mice that received BMT survived LCMV infection and developed a virus carrier status. Immu-
notherapy by adoptive transfer of naive splenocytes protected against low (200 PFU), but not high (2 106 PFU), doses of LCMV.
Attempts to control infection of high viral titers using strongly elevated frequencies of activated LCMV-specific T cells failed to
control virus and resulted in immunopathology and death. In contrast, virus neutralizing Abs combined with naive splenocytes
were able to efficiently control high-dose LCMV infection without associated side effects. Thus, cell transfer combined with
neutralizing Abs represented the most effective means of controlling BMT-associated opportunistic viral infection in our in vivo
model. These data underscore the in vivo efficacy and immunopathological “safety” of neutralizing antibodies. The Journal of
Immunology, 2005, 175: 5524–5531.
B one marrow transplantation (BMT)4 is currently used asa therapy for leukemia (1–4) and severe genetic disor-ders such as Wiskott-Aldrich syndrome (5, 6). In addi-
tion, it demonstrates some potential in the treatment of some ag-
gressive autoimmune diseases (7, 8). However, associated with
BMT are several side effects including alloreactivity, pancytope-
nia, and a high risk of opportunistic infection by viruses, fungi, and
parasites (9). For instance, infections with varizella-zoster virus
occur in up to 40% of bone marrow (BM) recipients and, if left
untreated, result in a mortality rate of 30% (10). Fifteen percent
of BMT patients develop CMV pneumonia, which results in le-
thality for up to 50% of cases (11), whereas 6% (12) of BMT
patients suffer from aspergillosis, for which mortality rates ap-
proach 100% (13–16). Notable but less frequent infections noted in
BMT patients include Toxoplasma gondii, Pneumocystis carinii,
and several bacterial and viral species including Streptococcus
pneumoniae, Listeria monocytogenes, respiratory syncytial virus,
and human herpes virus 6 (9).
Pharmacotherapy is commonly used in the treatment of BM re-
cipients; however, if given late, it is ineffective against invasive
aspergillosis or CMV and can result in the emergence of drug-
resistant variants (14, 17–21). Immunotherapy has been proposed
recently as an alternative and effective means of pathogen control
after BMT. Transfer of viral-specific CD8 T cells has been used
to treat patients suffering from infection with CMV (22–24) or
EBV (25, 26), and Ab transfer was demonstrated to abrogate as-
pergillosis in an experimental model of BMT (27).
To analyze the potential and limitations of cellular and humoral
adoptive immunotherapy associated with BMT, we examined
mouse infection with lymphocytic choriomeningitis virus (LCMV)
immediately after BMT. Although LCMV infection is not a note-
worthy complication after BMT in humans, it represents the well-
characterized prototypic poorly cytopathic virus that is controlled
in a CD8 T-cell-dependent manner, persists lifelong similar to
human CMV (28–30), and has been reported to reactivate in or-
gans during organ transplantation (31). Furthermore, LCMV neu-
tralizing Abs are induced rarely after single infection and therefore
are thought to play a minor role at least in early virus control
(32–34). In our model, we irradiated recipient C57BL/6 mice le-
thally, transferred syngeneic BM, and infected mice with different
doses of LCMV. In parallel, we treated recipient mice with naive
or specifically activated T cells or with neutralizing Abs alone or
in combination (Table I).
Here, we show that cellular immunotherapy with supplemented
protective Abs is the most effective means to protect BMT recip-
ients from opportunistic, clinically persistent, and immunopathol-
ogy causing viral infection.
Materials and Methods
Mice and viruses
LCMV strain WE was originally obtained from F. Lehmann-Grube (Hei-
nrich Pette Institute, Hamburg, Germany) and propagated on L929 cells.
Viral titers were measured using a plaque-forming assay (35). Splenocytes
from C57BL/6 mice, LCMV-gp61/I-Ab-specific TCR-transgenic mice
(SMARTA) (36), and LCMV-gp33/H-2Db-specific TCR-transgenic mice
(318) (37) were used for adoptive transfer. All mice used in this study were
maintained on the C57BL/6 background and housed under specific patho-
gen-free conditions.
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BMT and adoptive transfer
Mice were lethally irradiated (950 rad) on day 1. On day 0, 8  106 BM
cells, generated by flushing the femur and tibia of naive C57BL/6 mice,
were injected i.v. BM was not T cell depleted and would therefore lead to
minimal transfer of LCMV-specific T cells (Table I; Ref. 51). Recipient
and donor mice were age and sex matched. For immunotherapy, mice were
also given injections of 107 of the indicated splenocytes on day 0 or 200 l
of hyperimmune serum (titer, 1:4000). Activated LCMV-specific T cells
were generated in vivo by infected mice 8 days before with 2  106 PFU
of recombinant vaccinia expressing the LCMV glycoprotein (vaccG2) (38).
For adoptive transfer of CD8-depleted cells, donor mice were given injec-
tions of 3 mg of anti-CD8 Ab (YTS 169.8) on days 3 and 1. Hyper-
immune serum was generated in mice infected with 105 PFU of LCMV-
WE, boosted by subsequent viral infection on days 30 and 60, and bled
20–40 days after the last infection.
FACS analysis
FACS analysis was performed as described previously (39). Briefly, 106
splenocytes or BM cells were stained using PE-labeled LCMV-WE GP33
tetramer (GP33-Db) (39) for 15 min at 37°C, followed by staining with
anti-CD8-APC, anti-V2-FITC (for detection of transgenic LCMV-spe-
cific CD4 T cells), or anti CD4-PercP (BD Pharmingen) for 30 min at
4°C. Intracellular cytokine staining was performed using 106 splenocytes
previously incubated for 6 h at 37°C in RPMI 1640 containing 10% FCS,
antibiotics, and 25 U/ml IL-2 and stimulated with gp33 (107 M), gp61
(106 M), or left untreated. Brefeldin A (Sigma-Aldrich) was added (final
concentration, 5 g/ml) after 1 h of incubation. At the end of the stimu-
lation period, splenocytes were surface stained with anti-CD4 FITC, anti
CD4-PE, anti-CD8-PercP, or anti-CD8-PE (BD Pharmingen) for 30 min at
4°C. Cells were fixed and permeabilized using 4% paraformaldehyde in
PBS containing 0.1% saponin for 10 min at room temperature, stained with
anti-IFN--APC (BD Pharmingen), and analyzed using a FACSCalibur
and Cell Quest software.
Histology
Histological analysis was performed on tissue fixed in 4% formalin or snap
frozen and stained with eosin G and thiazine dye (Diff-Quik; Dade Be-
hring) or with goat mAbs against murine CD4 (YTS 191) or CD8 (YTS
169), respectively. Goat mAbs were detected using alkaline phosphatase-
labeled donkey anti-goat Abs (Jackson ImmunoResearch Laboratories) and
alkaline phosphatase visualized using naphthol AS-BI (6-bromo-2-hy-
droxy-3-naphtholic acid 2-methoxy anilide) phosphate and new fuchsin as
a substrate. The presence of alkaline phosphatase activity yielded a red
reaction product.
Statistical analysis
All data are expressed as mean  SEM. Unless mentioned otherwise, the
different treatment groups involved the use of six animals in at least two
independent experiments. Analysis of organ titers and intracellular cyto-
kine stainings were performed within groups of two to six animals.
Results
LCMV infection of BM recipients results in persistent LCMV
viremia
Specific pathogen-free C57BL/6 mice were lethally irradiated (950
rad), treated the next day with 8  106 syngenic BM cells, and
infected with 200 PFU (low-dose) or 2  106 PFU (high-dose) of
LCMV-WE. After low-dose LCMV-WE infection, the virus could
not be detected in the blood before day 10; thereafter, blood viral
titers rose steadily, reaching a peak of 1  105 PFU/ml on day 20
and remaining at this level for the remainder of the 50-day exper-
imental period (Fig. 1A). Infection with a high dose of LCMV-WE
resulted in the quicker appearance of blood viral titers (day 5).
However, the maximal virus blood titer was similar to that ob-
served after low-dose infection, and this level was maintained
throughout the remainder of the experiment (Fig. 1A). Viral titers
from the liver, lung, spleen, and kidney were analyzed at day 50
after infection, and all organs from mice infected with low or high
doses of LCMV-WE were found to contain between 1  107 and
1  108 PFU of virus, indicating that all mice had reached a virus-
carrier status (Fig. 1B) (28, 40). Of note, all carrier mice survived
the 50-day period, probably due to the specific pathogen-free con-
ditions used (data not shown) (40).
Virus-infected BM recipients were also examined for the pres-
ence of LCMV-specific CD8 T cells. In normal C57BL/6 mice,
tetramer staining using the LCMV-glycoprotein-derived epitope
(gp33) revealed the presence of significant numbers of virus-spe-
cific CD8 T cells 50 days after infection with low or high doses
of LCMV-WE (Fig. 1, D and F). In contrast, mice that underwent
BMT revealed absence of tetramer-positive CD8 T cells (Fig. 1,
C and E). To rule out the possibility that these cells had down-
regulated the TCR, we stimulated splenocytes in vitro with
gp33 and examined IFN- production. This assay confirmed our
observation that no LCMV-specific CD8 T cells were present
in mice having previously undergone BMT (data not shown).
We consider it likely that the absence of LCMV-specific CD8
T cells in BM recipients results from negative selection of these
cells in the thymus, or from peripheral exhaustion induced by
persisting virus (41).
Immunotherapy with naive splenocytes prevents the development
of an LCMV-carrier status in a CD8 T cell-dependent manner
The absence of LCMV-specific CD8 T cells in BM recipients
lead us to investigate whether immunotherapy with naive C57BL/6
splenocytes would be able to control viral spread. After BMT, we
Table I. Summary of transferred immune components
LCMV-Specific
CD4 T Cells
(total number)
LCMV-Specific
CD8 T Cells
(total number)
LCMV
Neutralizing
Ab (titer)
0a 0a 1:10
Naive splenocytes 10 10 1:10
Naive TCR-tg 318 splenocytes 10 5 105 1:10
Activated TCR-tg 318 splenocytes 2 105 5  105 1:10
Naive TCR-tg SMARTA splenocytes 1 106 0 1:10
Naive TCR-tg 318/SMARTA splenocytes 1 106 5  105 1:10
Hyperimmune serum 0 0 1:400
Hyperimmune serum  naive splenocytes 10 10 1:400
Immunotherapy of BMT recipients. Values represent the estimated numbers of LCMV-specific cells in BMT recipients after
transfer of splenocytes (per mouse) or Ab titers in the serum of recipient mice after transfusion of hyperimmune serum.
a BM from naive C57BL/6 mice contained 0.40 0.10% naive CD8 and 0.57 0.06% naive CD4 T cells (in accordance
with Ref. 51). We transferred probably one LCMV-specific CD8 T cell and one specific CD4 T cell within the BM in one of
three mice.
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treated mice with 107 naive C57BL/6 splenocytes on day 0. After
infection with a low dose of LCMV-WE (day 0), only one from a
total of six mice receiving naive splenocytes demonstrated virus
titers in blood, and virus was cleared in this mouse by day 15 (Fig.
2A). No virus was detected in any of the examined organs from
these mice (Fig. 2B). Both virus-specific CD8 and CD4 T cells
were found to be present and functional (Fig. 2, D–F). Control
of viral infection was clearly CD8 T cell dependent, because
adoptive transfer of CD8-depleted splenocytes failed to mediate
viral clearance (Fig. 2A). Mice that received naive splenocytes and
were infected with a high dose of LCMV-WE were unable to
control viral spread (Fig. 2, A and B), despite the presence of
functional virus-specific CD8 T cells (Fig. 2, G–I). All mice
receiving a low dose of LCMV-WE and five of six mice receiving
a high dose of LCMV-WE survived immunotherapy with naive
splenocytes (Fig. 2C), and immunopathology was limited (data not
shown). The latter result probably reflected at least partial exhaus-
tion of virus-specific CD8 T cells (41).
Immunotherapy with virus-specific CD8 T cells results in
immunopathology
To analyze whether increased precursor frequencies of virus-spe-
cific CD8 T cells could provide improved protection against
LCMV infection, we treated BMT recipients with 107 splenocytes
from naive or previously immunized 318 mice in which 50% of
CD8 T cells carry a transgenic TCR specific for LCMV-GP33–41
(gp33) (37). Naive splenocytes from 318 TCR-transgenic mice
were able to inhibit viral spread after infection with a low dose of
LCMV-WE, with very low or no titers of virus in any of the organs
tested (Fig. 3B). Both virus-specific CD8 and CD4 T cells were
found to be present and functional (Fig. 3, D–F), and all mice
survived the immunotherapy (Fig. 3C). In contrast, these mice
were not able to control viral spread after infection with a high
dose of LCMV-WE (Fig. 3A), and the majority of mice had died
by day 17 after infection (Fig. 3C).
Immunotherapy with activated splenocytes from previously im-
munized 318 TCR-transgenic mice (with LCMV GP-recombinant
vaccinia virus, vaccG2) was also unable to protect BM recipients
against infection with a high dose of LCMV-WE, with all mice
exhibiting initially high blood viral titers (Fig. 3A) and half of the
mice dying by day 10 (Fig. 3C). The surviving mice were found to
eventually clear the virus (Fig. 3, A and B) and displayed func-
tional CD4 and CD8 T cells in the spleen (Fig. 3, G–I). Mice
that died exhibited extensive CD8 T cell infiltration of various
organs, including the BM (Fig. 4A and data not shown), and
demonstrated severely reduced numbers of hemopoietic precur-
sor cells in the BM (Fig. 4B). These mice also displayed re-
duced hemoglobin (6.5  1.6 g/dl; n  3) compared with mice
not receiving immunotherapy (13.6  1.7 g/dl; n  3). To-
gether, these data indicated that the transfer of high numbers of
LCMV-specific CD8 T cells prevented T cell exhaustion and
promoted rapid T cell expansion and viral clearance; however,
such treatment carried a high risk of inducing immunopathol-
ogy and early death.
Immunotherapy with virus-specific CD4 T cells resulting in
immunopathology
To determine the ability of increased precursor frequencies of
virus-specific CD4 T cells to mediate viral clearance in BM
recipients, we also treated BM-transplanted mice with 107
splenocytes from SMARTA mice, in which 95% of CD4 T
cells carry a transgenic TCR specific for the LCMV-glycopro-
tein-derived epitope gp61 and which exhibit severely reduced
numbers of CD8 T cells (36). These mice were unable to
control infection with either low or high doses of LCMV-WE
(Fig. 5A), and all mice died before day 20 (Fig. 5B). FACS
analysis indicated the presence of large numbers of functional
LCMV-specific TCR-transgenic CD4 T cells in the spleen and
the BM of these mice (Fig. 5, D and F). Histological analysis
FIGURE 1. LCMV infection during BMT causes
persistent LCMV viremia. Mice were lethally irradiated
(950 rad) on day 1. On day 0, 8  106 BM cells were
injected and mice were infected with LCMV-WE at 200
PFU (F) or 2 106 PFU (f). A, Blood viral titers (n
6). B, Virus titers in organs at day 50 after infection
(n  3). C–F, Representative tetramer stain at day 50
from splenocytes of mice that received BMT and
LCMV infection at 200 PFU (C) or 2  106 PFU (E).
Mice that did not receive BMT and were infected with
200 PFU (D) or 2  106 PFU (F) served as positive
control. Uninfected C57BL/6 mice served as negative
control (0.22  0.06%). Values are given as mean 
SEM derived from staining three individual mice per
treatment group.
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also revealed that large numbers of CD4 T cells were infil-
trating the liver and lung (Fig. 4A). Thus, immunotherapy with
high numbers of LCMV-specific CD4 T cells did not mediate
viral clearance but caused severe immunopathology and early
death. Functional gp33-specific CD8 T cells could be detected
in the spleen and BM (Fig. 5, C and E) and were likely to
FIGURE 2. Adoptive transfer of naive splenocytes prevents develop-
ment of a LCMV-carrier status in a CD8 T cell-dependent manner. Mice
were subjected to BMT as detailed in Fig. 1. Mice were also treated with
107 naive C57BL/6 splenocytes and infected with LCMV-WE at 200 PFU
(circles) or 2  106 PFU (squares). A, Blood viral titers (n  6). An
additional group of mice received CD8 T cell-depleted splenocytes and
were infected with 200 PFU of LCMV-WE (E; n  4). B, Virus titers in
organs at day 50 after infection (n  3–5). C, Survival curves (n  6).
D–F, On day 50, splenocytes from BMT mice treated with naive C57BL/6
splenocytes and infected with 200 PFU of LCMV-WE were stained for gp33-
specific T cells by tetramer (D) and stained for intracellular IFN- after re-
stimulation with the CD8 T cell epitope gp33 (E) and the CD4 T cell epitope
gp61 (F). Values are given as mean  SEM derived from staining three in-
dividual mice per treatment group. G–I, On day 50, splenocytes from BMT
mice treated with naive C57BL/6 splenocytes and infected with 2 106 PFU
of LCMV-WE were stained for gp33-specific T cells by tetramer (G) and
stained for intracellular IFN- after restimulation with the CD8 T cell epitope
gp33 (H) and the CD4 T cell epitope gp61 (I). Values are given as mean 
SEM derived from staining three individual mice per treatment group.
FIGURE 3. Virus-specific CD8 T cells mediate immunopathology.
Mice were subjected to BMT as detailed in Fig. 1. Mice were also given
injections of 107 naive (filled symbols) or activated (open symbols) spleno-
cytes from 318 TCR-transgenic mice and infected with LCMV-WE at 200
PFU (circles) or 2  106 PFU (squares). A, Blood viral titers (n  6). B,
Virus titers in organs at day 50 after infection (n  3). C, Survival curves
(n  6). D–F, On day 50, splenocytes from BMT mice treated with naive
318 TCR-transgenic splenocytes and infected with 200 PFU of LCMV-WE
were stained for gp33-specific T cells by tetramer (D) and stained for
intracellular IFN- after restimulation with the CD8 T cell epitope gp33
(E) and the CD4 T cell epitope gp61 (F). Values are given as mean SEM
derived from staining three individual mice per treatment group. G–I, On
day 50, splenocytes from BMT mice treated with activated 318 TCR-trans-
genic splenocytes and infected with 2  106 PFU of LCMV-WE were
stained for gp33-specific T cells by tetramer (G) and stained for intracel-
lular IFN- after restimulation with the CD8 T cell epitope gp33 (H) and
the CD4 T cell epitope gp61 (I). Values are given as mean  SEM derived
from staining three individual mice per treatment group.
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represent endogenous cells because SMARTA mice contained
low numbers of CD8 T cells (36).
We also investigated the effect of immunotherapy with in-
creased precursor frequencies of both CD4 and CD8 T cells
specific for LCMV. Mice that underwent BMT were treated with
splenocytes from SMARTA and 318 mice and infected with a high
dose of LCMV-WE. The virus was not cleared, and death occurred
within 20 days (data not shown).
Immunotherapy with neutralizing Abs results in viral clearance
Cellular immunotherapy was effective at clearing low-dose viral
infections of BM recipients but could not protect BM recipients
from high-dose viral infection. We therefore analyzed the ability of
neutralizing antibodies, present in hyperimmune serum, to protect
against persistent infection and immunopathological disease. Ad-
ministration of as little as 200 l of hyperimmune serum (titer,
1:4000) inhibited viral spread in all BM-transplanted mice infected
with low-dose LCMV (Fig. 6A). Moreover, all organs analyzed on
day 50 were free of detectable virus (Fig. 6B), all mice survived
(Fig. 5C), and LCMV-specific CD4 and CD8 T cells were
present and functional (Fig. 6, D–F). These cells presumably arose
from donor BM, and their presence indicated that administration of
hyperimmune serum protected the endogenous T cell response
from rapid exhaustion.
Hyperimmune serum could also prevent early viral spread after
high-dose LCMV infection (Fig. 6A). However, by day 50 after
infection, viral titers were high in the blood (Fig. 6A) and other
analyzed organs (B), and no functional LCMV-specific T cells
were detected (data not shown). These mice showed little apparent
immunopathology, and five of six mice survived (Figs. 4A and
6C). In an attempt to improve the immunotherapeutic treatment of
BM recipients receiving high-dose viral infection, we treated mice
with both hyperimmune serum and naive splenocytes. This treat-
ment was successful in that no virus was detected in the blood (Fig.
6A) or any of the organs analyzed on day 50 (Fig. 6B). Moreover,
all mice survived the immunotherapy (Fig. 6C), and the spleen was
found to contain significant numbers of functional LCMV-specific
CD4 and CD8 T cells (Fig. 6, G–I). This result demonstrated
that a combination of transferred cellular and humoral immunity
controlled a 104-fold higher viral load than either component
alone.
FIGURE 4. Histological analysis of immunopathology. Mice were sub-
jected to BMT as detailed in Fig. 1 and infected with 2  106 PFU of
LCMV-WE. A, Histological analysis of various organs from mice also
given injections of naive splenocytes from SMARTA TCR-transgenic mice
(left panels; day 10), naive splenocytes from 318 TCR-transgenic mice
(middle panels; day 15), or hyperimmune serum (right panels; day 50).
Sections were stained with Abs directed against murine CD8 or CD4, as
indicated. The dark red color represents positive staining. Mice subjected
to BMT and LCMV infection, but not receiving immunotherapy, did not
display any immunopathology (data not shown). One representative slide
of three is shown. Scale bars, 50 m. B, One (of three) representative BM
smear of BMT mice infected with 2  106 PFU of LCMV-WE 15 days
before (right) or of LCMV-infected BMT mice also given injections of
naive splenocytes from 318 TCR-transgenic mice (left) stained with eosin
G and thiazine dye. Scale bars, 50 m. One section (50 m long) is shown
in higher magnification (insets).
FIGURE 5. Virus-specific CD4 T cells mediated immunopathology.
Mice were subjected to BMT as detailed in Fig. 1. Mice were also given
injections of 107 naive splenocytes from SMARTA TCR-transgenic mice
and infected with LCMV-WE at 200 PFU (F) or 2 106PFU (f). A, Viral
titers from liver, lung, spleen, kidney, and blood (given in PFU/organ or
PFU/ml blood; n  2–6) at day 10 after infection. B, Survival curves (n 
6). C–F, On day 50, splenocytes and BM from BMT mice treated with
naive SMARTA TCR-transgenic splenocytes and infected with 200 PFU of
LCMV-WE were stained for gp33-specific CD8 T cells by tetramer (C) and
transgenic gp61-specific CD4 T cells by anti-V2 Ab (D). Splenocytes
were stained for intracellular IFN- after restimulation with the CD8 T cell
epitope gp33 (E) or the CD4 T cell epitope gp61 (F). Values are given as
mean  SEM derived from staining three individual mice per treatment
group.
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Hyperimmune serum prevents immunopathology
Hyperimmune serum appeared to be of benefit for the clearance of
virus. We asked whether this reduction in viral load could also
ameliorate the outcome of immunopathology. Indeed, immunopa-
thology was absent if mice were treated with both immunopathol-
ogy causing 318 CD8 T cells and hyperimmune serum on the day
of infection (Fig. 7A). Virus was cleared until day 14 (Fig. 7B) but
was still able to activate virus-specific CD8 T cells, because they
showed high frequencies of tet-gp33 cells in the blood (Fig. 7C).
One-half of the gp33-specific CD8 T cells contained an IL7-
Rhigh-expressing memory population (Fig. 7D), whereas the oth-
ers still were effector T cells (IL7-Rlow) (42). Nearly all T cells
from mice that were not treated with hyperimmune serum showed
an effector phenotype (IL-7Rlow) that is in agreement with high
viral load and immunopathology (43). Because hyperimmune se-
rum, given at the time of infection, could inhibit immunopathol-
ogy, we wondered whether hyperimmune serum could even reduce
ongoing immunopathology. Therefore, we supplied BM-trans-
planted mice with 107 318 splenocytes. Seven days later, one of
eight mice died and the other mice showed clinical signs of im-
munopathology. At that time, we treated three mice with hyper-
immune serum. Although hyperimmune serum slightly reduced
viral load (Fig. 7B), mice did not show a reduction in clinical signs,
and all mice died between days 10 and 15 (Fig. 7A). Blood lym-
phocytes displayed high frequencies of tet-gp33 T cells all ex-
pressing low levels of IL-7R (Fig. 7, C and D).
Thus, hyperimmune serum was able to prevent immunopathol-
ogy; however, if given late, it had no benefit on survival.
FIGURE 6. Hyperimmune serum prevented viral spread and CD8 T
cell exhaustion without causing immunopathology. Mice were subjected to
BMT as detailed in Fig. 1. All mice were given injections of hyperimmune
serum containing neutralizing Abs and infected with LCMV-WE at 200
PFU (circles) or 2  106 PFU (squares). A third group of mice also re-
ceived naive C57BL/6 splenocytes (E). A, Percentage of carrier mice de-
termined by a viral load of 104 PFU/ml blood (n  6). B, Virus titers in
organs at day 50 after infection (n  3). C, Survival curves (n  6). D–F,
On day 50, splenocytes from BMT mice treated with hyperimmune serum and
infected with 200 PFU of LCMV-WE were stained for gp33-specific T cells
by tetramer (D) and stained for intracellular IFN- after restimulation with the
CD8 T cell epitope gp33 (E) and the CD4 T cell epitope gp61 (F). Values are
given as mean  SEM derived from staining three individual mice per treat-
ment group. G–I, On day 50, splenocytes from BMT mice treated with hy-
perimmune serum and naive C57BL/6 splenocytes and infected with 2 106
PFU of LCMV-WE were stained for gp33-specific T cells by tetramer (G) and
stained for intracellular IFN- after restimulation with the CD8 T cell epitope
gp33 (H) and the CD4 T cell epitope gp61 (I). Values are given as mean 
SEM derived from staining three individual mice per treatment group.
FIGURE 7. Hyperimmune serum prevented immunopathology. Mice
were subjected to BMT as detailed in Fig. 1. All mice were also given
injections of 107 naive splenocytes from 318 TCR-transgenic mice and
infected with 2  106 PFU of LCMV-WE. One group of mice was also
treated with hyperimmune serum on day 0 (n  4; f, filled bars). Another
group of mice was treated with hyperimmune serum on day 7 (n  3; ,
open bars). One group of mice was not treated with hyperimmune serum
(n  5; gray circles, gray bars). A, Survival curves. B, Virus titers in blood
at day 14 after infection. C, Blood lymphocytes were stained for gp33-
specific T cells by tetramer. Values are given as mean SEM derived from
staining three individual mice per treatment group. D, CD8 T cells, which
were tet-gp33, were analyzed for expression of IL-7R. One representa-
tive FACS blot and the summary of three to four mice per treatment group
is shown. , p  0.05.
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Discussion
Opportunistic infections frequently complicate the recovery of
BMT patients, and to date there is no satisfying mean of protecting
such patients. We investigated the potential of immunotherapeutic
strategies to prevent or lower the risk of opportunistic viral infec-
tion in the well characterized murine LCMV infection model. Al-
though LCMV itself is not an important human pathogen, it be-
haves partly similar to CMV, which is the most frequent pathogen
associated with human BMT. Like CMV, LCMV persists lifelong
in infected recipients and induces a strong CD8 T cell response
(29, 30), which is crucial for the control of the virus (28).
We showed that the adoptive transfer of CD8 T cells was able
to control viral spread after BMT but eventually resulted in severe
immunopathology, presumably caused by the lytic potential of
CD8 T cells and resultant tissue destruction. Adoptive immuno-
therapy with CD4 T cells also resulted in immunopathology, al-
though the mechanism by which this occurred is likely to be more
complex, possibly involving cytokines such as TNF- (44). Pre-
vious studies have shown that virus-specific CD4 T cells alone
are not able to control LCMV infection (36, 44), and in support of
this, we show that adoptive immunotherapy using CD4 T cells
alone was not able to prevent viral spread in BM recipients.
In many cases, T cell immunopathology resulted in death of
recipient mice, a phenomenon that probably is mediated at least in
part by the immunological destruction of the newly established
BM and resultant aplastic anemia (45, 46). Of interest, CMV re-
activation after human BMT is often associated with graft failure
and is thought to be mediated by virus-induced autoimmunity (47,
48). An additional complication that should be considered in hu-
man BMT patients is that immunopathology can be enhanced by
graft-vs-host reactions resulting from allogenic BMT.
Instead, our data indicate a potential role for neutralizing Abs in
the prevention of pathogenic infections after BMT. Under normal
circumstances, neutralizing Ab induction is delayed after infection
with LCMV, and were previously thought to play a minor role in
initial virus elimination. Nevertheless, treatment of LCMV-in-
fected BM recipient mice with hyperimmune serum was able to
reduce early viral spread and to prevent exhaustion of endogenous
viral-specific CD8 T cells, allowing efficient viral clearance. This
phenomenon may well apply to other noncytopathic or poorly cy-
topathic viruses, including perhaps HIV, hepatitis B virus, and
hepatitis C virus, and so neutralizing Abs may provide a useful
therapy for the treatment of ongoing persistent infections with
these viruses (49, 50). We found that immunopathology could be
prevented if neutralizing Abs were supplied early; however, if
given late, they demonstrated no benefit. From our experiments,
we may wish to speculate that those neutralizing Abs should be
giving shortly before or early after BMT.
In conclusion, we have completed a thorough comparison of the
ability of cellular and humoral immunotherapeutic strategies to
control chronic viral infection after BMT. These studies demon-
strated that naive splenocytes can prevent an infection with low but
not high doses of virus. Increased precursor frequencies of virus-
specific T cells resulted in immunopathology and death of BM
recipients. The combined use of neutralizing Abs and naive
splenocytes inhibited virus spread even after infection with high
doses of virus and allowed the development of endogenous virus-
specific CD8 T cells. Together, these data suggest that neutral-
izing Abs combined with limited numbers of CTLs may represent
a powerful tool for limiting opportunistic persistent viral infection
in BMT patients.
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